Back to the Top
I am planning for one biostudy for a molecule for which i am preparting twice a day formulation (NDA 505 (b) 2) and already thrice a day and Immediate release (four times a day) formulation is existing in the market. Can you please suggest me what should be RLD for me for US and Europe market and reference for the selection of the same.
Dr. Tushar Nahata
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "RLD selection" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)